000292539 001__ 292539
000292539 005__ 20241110013700.0
000292539 0247_ $$2doi$$a10.1158/1078-0432.CCR-24-1152
000292539 0247_ $$2pmid$$apmid:39207225
000292539 0247_ $$2ISSN$$a1078-0432
000292539 0247_ $$2ISSN$$a1557-3265
000292539 0247_ $$2altmetric$$aaltmetric:169027116
000292539 037__ $$aDKFZ-2024-01782
000292539 041__ $$aEnglish
000292539 082__ $$a610
000292539 1001_ $$00000-0002-6855-2982$$aHeinst, Lorena$$b0
000292539 245__ $$aExploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma.
000292539 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2024
000292539 3367_ $$2DRIVER$$aarticle
000292539 3367_ $$2DataCite$$aOutput Types/Journal article
000292539 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730707373_16201
000292539 3367_ $$2BibTeX$$aARTICLE
000292539 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292539 3367_ $$00$$2EndNote$$aJournal Article
000292539 500__ $$a2024 Nov 1;30(21):4974-4986
000292539 520__ $$aThe pathognomonic FUS::DDIT3 fusion protein drives myxoid liposarcoma (MLS) tumorigenesis via aberrant transcriptional activation of oncogenic signaling. Since FUS::DDIT3 has so far not been pharmacologically tractable to selectively target MLS cells, this study investigated the functional role of the cell cycle regulator WEE1 as novel FUS::DDIT3‑dependent therapeutic vulnerability in MLS.Immunohistochemical evaluation of the cell cycle regulator WEE1 was performed in a large cohort of MLS specimens. FUS::DDIT3 dependency and biological function of the G1/S cell cycle checkpoint were analyzed in a mesenchymal stem cell model and liposarcoma cell lines in vitro. WEE1 activity was modulated by RNAi‑mediated knockdown and the small molecule inhibitor MK-1775 (Adavosertib). An established MLS cell line-based chicken chorioallantoic membrane model was employed for in vivo confirmation.We demonstrate that enhanced WEE1 pathway activity represents a hallmark of FUS::DDIT3‑expressing cell lines as well as MLS tissue specimens and that WEE1 is required for MLS cellular survival in vitro and in vivo. Pharmacologic inhibition of WEE1 activity results in DNA damage accumulation and cell cycle progression forcing cells to undergo apoptotic cell death. In addition, our results uncover FUS::DDIT3-dependent WEE1 expression as an oncogenic survival mechanism to tolerate high proliferation and resulting replication stress in MLS. Fusion protein-driven G1/S cell cycle checkpoint deregulation via overactive Cyclin E/CDK2 complexes thereby contributes to enhanced WEE1 inhibitor sensitivity in MLS.Our preclinical study identifies WEE1-mediated replication stress tolerance as molecular vulnerability in FUS::DDIT3-driven MLS tumorigenesis that could represent a novel target for therapeutic intervention.
000292539 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000292539 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292539 7001_ $$0P:(DE-He78)1121dc6777ecb3a3e48075bbd16246f2$$aLee, Kwang$$b1$$udkfz
000292539 7001_ $$00000-0001-7918-1657$$aBerthold, Ruth$$b2
000292539 7001_ $$00000-0002-7485-8769$$aIsfort, Ilka$$b3
000292539 7001_ $$00009-0009-8728-7836$$aWosnig, Svenja$$b4
000292539 7001_ $$00009-0004-0145-6111$$aKuntze, Anna$$b5
000292539 7001_ $$00000-0003-0663-8382$$aHafner, Susanne$$b6
000292539 7001_ $$00000-0003-4936-4879$$aAltvater, Bianca$$b7
000292539 7001_ $$00000-0002-8672-5285$$aRössig, Claudia$$b8
000292539 7001_ $$00000-0002-1482-8875$$aÅman, Pierre$$b9
000292539 7001_ $$00000-0001-6788-4910$$aWardelmann, Eva$$b10
000292539 7001_ $$0P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aScholl, Claudia$$b11$$udkfz
000292539 7001_ $$aHartmann, Wolfgang$$b12
000292539 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b13
000292539 7001_ $$00000-0002-5842-1196$$aTrautmann, Marcel$$b14
000292539 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-24-1152$$n21$$p4974-4986$$tClinical cancer research$$v30$$x1078-0432$$y2024
000292539 909CO $$ooai:inrepo02.dkfz.de:292539$$pVDB
000292539 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1121dc6777ecb3a3e48075bbd16246f2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292539 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000292539 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000292539 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000292539 9141_ $$y2024
000292539 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000292539 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2023-08-25
000292539 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x0
000292539 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000292539 9201_ $$0I:(DE-He78)B290-20160331$$kB290$$lAngewandte Funktionelle Genomik$$x2
000292539 980__ $$ajournal
000292539 980__ $$aVDB
000292539 980__ $$aI:(DE-He78)B340-20160331
000292539 980__ $$aI:(DE-He78)HD01-20160331
000292539 980__ $$aI:(DE-He78)B290-20160331
000292539 980__ $$aUNRESTRICTED